TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed. ...

Core Viewpoint - Quantum BioPharma Ltd. has successfully closed a non-brokered private placement, issuing 30 Class A Multiple Voting Shares at a price of $25 each, resulting in gross proceeds of $750 million [1][2]. Offering Details - The securities issued are subject to a statutory hold period of four months plus a day from issuance as per Canadian securities laws [2]. - Proceeds from the offering will be utilized for general working capital purposes [2]. Related Party Transactions - Xorax Family Trust and Fortius Research and Trading Corp., both associated with company insiders, purchased all Class A Multiple Voting Shares in the offering, qualifying as a related-party transaction under MI 61-101 [3]. - The company has relied on exemptions from formal valuation and minority shareholder approval requirements as the transaction did not exceed 25% of the company's market capitalization [3]. Corporate Update - The company has terminated its at-the-market offering agreement with H.C. Wainwright & Co., effective December 6, 2025, with the termination taking effect on December 20, 2025 [16]. - No Class B Subordinate Voting Shares have been sold under the previous sales agreement, which allowed for the sale of up to $21.225 million worth of shares [17]. Debt Settlement - Quantum BioPharma has settled $260,000 owed to an arm's length creditor by issuing 17,626 Class B Subordinate Voting Shares at a deemed price of $14.75 per share [18]. Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [19]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until reaching $250 million, after which the royalty will drop to 3% [19].

Core Insights - Quantum BioPharma Ltd. is involved in a USD $700 million lawsuit against CIBC and RBC, alleging stock market manipulation through "stock spoofing" [2][3] - The company emphasizes the importance of addressing stock market manipulation for the benefit of shareholders and the integrity of publicly traded companies [3] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [4] - The company is developing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation in MS [4] - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is associated with its product unbuzzd™ and has a royalty agreement that could yield up to $250 million [4] Legal and Regulatory Context - The investigative series by CTV News highlights a trend of increasing market manipulation cases in Canada, underscoring the relevance of Quantum BioPharma's legal actions [2][3] - The company is actively encouraging whistleblowers to come forward with information regarding illegal market manipulation, offering rewards up to USD $7 million [3]

Core Insights - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," which has led to a USD $700 million lawsuit [2][4]. - The investigative series aired by CTV News highlights the impact of stock spoofing on retail investors and the broader implications for market integrity [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in reversing nerve cell degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their trading platforms [4]. - The company aims to use the exposure from the lawsuit to protect other firms and investors from similar experiences of market manipulation [4].

Core Viewpoint - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," with a lawsuit amounting to USD $700 million [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which has shown potential in reversing nerve cell degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The ongoing lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their platforms [4]. - The investigative series by CTV News highlights the broader implications of stock spoofing on retail investors and the integrity of the market [2][4].

Core Viewpoint - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," with a lawsuit amounting to USD $700 million [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The ongoing lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their platforms [4]. - The investigative series by CTV News highlights the broader implications of stock spoofing on retail investors and the integrity of the market [2][4].

Core Insights - Quantum BioPharma Ltd. is facing allegations of stock market manipulation, which has led to a USD $700 million lawsuit against CIBC and RBC, two of Canada's largest banks [2][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4]. Industry Context - The investigative series by CTV News highlights the illegal practice of "stock spoofing," which is a form of market manipulation that affects retail investors and can derail important research and development efforts in the biopharmaceutical sector [2][3].

Core Insights - Quantum BioPharma Ltd. is facing allegations of stock market manipulation, which is the focus of a three-part investigative series by CTV News' W5 [1][2] - The company has filed a USD $700 million lawsuit against CIBC and RBC, two of Canada's largest banks, related to these allegations [2] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4] - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] Legal Context - The investigative series highlights the illegal practice of "stock spoofing," which has reportedly harmed retail investors and is central to Quantum BioPharma's legal claims [2][3] - CEO Zeeshan Saeed emphasized the importance of addressing stock market manipulation to protect other companies and their stakeholders from similar experiences [3]

Core Insights - Quantum BioPharma Ltd. reported strong financial results for Q3 2025, showcasing significant improvements in shareholder equity and a reduction in liabilities, indicating a robust financial position and operational momentum [2][3][15] Financial Performance - Shareholder equity increased by 275%, rising from US$2 million to US$7.5 million [5] - Total liabilities decreased by 50%, from US$13.2 million to US$6.6 million, primarily due to the elimination of convertible debentures [5][6] - The debt-to-equity ratio improved by 87%, from 6.47x to 0.89x, reflecting a stronger balance sheet [5] - General and Administrative expenses decreased by approximately US$210,000 compared to the same quarter the previous year [6] - The current ratio improved from 0.78x to 1.41x, indicating enhanced liquidity [5] Clinical Development - The company is advancing its multiple sclerosis drug, Lucid-21-302 ("Lucid-MS"), which has shown promise in pre-clinical studies to halt nerve demyelination [4][15] - A joint PET study with Massachusetts General Hospital has commenced, with the first patient scanned to validate a novel imaging technique for monitoring myelin integrity in MS [7][15] - Phase 1 oral toxicity studies of Lucid-MS have been completed, showing no toxicity or side effects [12] Product Development and Market Growth - Unbuzzd Wellness Inc., the licensee of Quantum's unbuzzd product, is preparing for a capital raise of up to US$5 million in anticipation of a possible IPO, with no equity dilution for Quantum shareholders [8][13] - Health Canada granted a Product License for Qlarity, a natural health product, allowing Quantum to sell it in Canada [15] Legal Matters - Quantum has filed a memorandum opposing a motion to dismiss in its lawsuit against CIBC and RBC regarding alleged stock market manipulation [9]

Core Viewpoint - Quantum BioPharma Ltd. is conducting a non-brokered private placement of up to 30 Class A Multiple Voting Shares at a price of $25 per share, aiming for gross proceeds of up to $750 million, primarily to enhance voting rights and for general working capital purposes [1][2]. Group 1: Offering Details - The private placement is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, existing holders of Class A Multiple Voting Shares [1][3]. - If fully subscribed, the voting rights attached to Class A Multiple Voting Shares will increase to 75.27%, nearly restoring the percentage to that at the time of the company's IPO in 2018 [2]. - The board of directors unanimously approved the Offering, excluding Saeed and Durkacz from discussions due to their interests [2]. Group 2: Related Party Transactions - The Offering involves related-party transactions as it is anticipated that Xorax Family Trust and Fortius Research and Trading Corp. will purchase all Class A Multiple Voting Shares issued [3]. - The transaction is expected to be exempt from formal valuation and minority shareholder approval requirements under MI 61-101, as the fair market value will not exceed 25% of the company's market capitalization [3]. Group 3: Shareholder Structure - Prior to a recent transfer, the Transferor and Joint Actors held approximately 50% of the outstanding Class A Multiple Voting Shares and 24.85% of the voting rights attached to all voting securities [7]. - Following the transfer of 77,000 Class B Subordinate Voting Shares, the ownership structure changed, with the Transferor and Joint Actors now holding approximately 23.77% of the voting rights [8]. Group 4: Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at treating multiple sclerosis [12]. - The company retains a 20.10% ownership in Unbuzzd Wellness Inc., which includes a royalty agreement for sales from its product unbuzzd™ [12].